Induction of complement C3a receptor responses by kallikrein-related peptidase 14

Journal of Immunology

Volumn 191, Issue 7, 2013, Pages 3858-3866

  Oikonomopoulou, Katerina ^a,b   Deangelis, Robert A ^a   Chen, Hui ^a   Diamandis, Eleftherios P ^b,c   Hollenberg, Morley D ^d,e   Ricklin, Daniel ^a   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3A RECEPTOR; COMPLEMENT RECEPTOR; KALLIKREIN RELATED PEPTIDASE 14; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOMODULATION; IN VITRO STUDY; INNATE IMMUNITY; INTRACELLULAR SIGNALING; MASS SPECTROMETRY; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN PROCESSING; RAT; TISSUE DISTRIBUTION;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C3A; COMPLEMENT C5; DISEASE MODELS, ANIMAL; EDEMA; HUMANS; KALLIKREINS; MICE; MICE, KNOCKOUT; PROTEOLYSIS; RECEPTORS, COMPLEMENT;

EID: 84885098136     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202999     Document Type: Article

References (52)

1. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11:785-797.
2. Le Friec, G., and C. Kemper. 2009. Complement: coming full circle. Arch. Immunol. Ther. Exp. 57:393-407.
3. Klos, A., E. Wende, K. J. Wareham, and P. N. Monk. 2013. International Union of Pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol. Rev. 65:500-543.
4. Eggertsen, G., U. Hellman, A. Lundwall, J. Folkersen, and J. Sjöquist. 1985. Characterization of tryptic fragments of human complement factor C3. Mol. Immunol. 22:833-841.
5. Wetsel, R. A., and W. P. Kolb. 1982. Complement-independent activation of the fifth component (C5) of human complement: limited trypsin digestion resulting in the expression of biological activity. J. Immunol. 128:2209-2216.
6. Wiggins, R. C., P. C. Giclas, and P. M. Henson. 1981. Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J. Exp. Med. 153:1391-1404.
7. Di Scipio, R. G. 1982. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 45:587-595.
8. Amara, U., M. A. Flierl, D. Rittirsch, A. Klos, H. Chen, B. Acker, U. B. Brückner, B. Nilsson, F. Gebhard, J. D. Lambris, and M. Huber-Lang. 2010. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 185:5628-5636.
9. Orr, F. W., J. Varani, D. L. Kreutzer, R. M. Senior, and P. A. Ward. 1979. Digestion of the fifth component of complement by leukocyte enzymes: sequential generation of chemotactic activities for leukocytes and for tumor cells. Am. J. Pathol. 94:75-83.
10. Fukuoka, Y., H. Z. Xia, L. B. Sanchez-Muñoz, A. L. Dellinger, L. Escribano, and L. B. Schwartz. 2008. Generation of anaphylatoxins by human β-tryptase from C3, C4, and C5. J. Immunol. 180:6307-6316.
11. Wingrove, J. A., R. G. Di Scipio, Z. Chen, J. Potempa, J. Travis, and T. E. Hugli. 1992. Activation of complement components C3 and C5 by a cysteine proteinase (gingipain-1) from Porphyromonas (Bacteroides) gingivalis. J. Biol. Chem. 267:18902-18907.
12. Borgoño, C. A., and E. P. Diamandis. 2004. The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4:876-890.
13. Sotiropoulou, G., and G. Pampalakis. 2010. Kallikrein-related peptidases: bridges between immune functions and extracellular matrix degradation. Biol. Chem. 391:321-331.
14. Eissa, A., and E. P. Diamandis. 2008. Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions. Biol. Chem. 389:669-680.
15. Klos, A., A. J. Tenner, K. O. Johswich, R. R. Ager, E. S. Reis, and J. Kohl. 2009. The role of the anaphylatoxins in health and disease. Mol. Immunol. 46:2753-2766.
16. Nestle, F. O., P. Di Meglio, J. Z. Qin, and B. J. Nickoloff. 2009. Skin immune sentinels in health and disease. Nat. Rev. Immunol. 9:679-691.
17. Pasch, M. C, N. H. Van Den Bosch, M. R. Daha, J. D. Bos, and S. S. Asghar. 2000. Synthesis of complement components C3 and factor B in human keratinocytes is differentially regulated by cytokines. J. Invest. Dermatol. 114:78-82.
18. Dovezenski, N., R. Billetta, and I. Gigli. 1992. Expression and localization of proteins of the complement system in human skin. J. Clin. Invest. 90:2000-2012.
19. Purwar, R., M. Wittmann, J. Zwirner, M. Oppermann, M. Kracht, O. Dittrich-Breiholz, R. Gutzmer, and T. Werfel. 2006. Induction of C3 and CCL2 by C3a in keratinocytes: a novel autocrine amplification loop of inflammatory skin reactions. J. Immunol. 177:4444-4450.
20. Kotnik, V. 2011. Complement in skin diseases. Acta Dermatovenerol. Alp. Panonica Adriat. 20:3-11.
21. Markiewski, M. M., and J. D. Lambris. 2009. Unwelcome complement. Cancer Res. 69:6367-6370.
22. Jean, D., M. Bar-Eli, S. Huang, K. Xie, F. Rodrigues-Lima, J. Hermann, and R. Frade. 1996. A cysteine proteinase, which cleaves human C3, the third component of complement, is involved in tumorigenicity and metastasis of human melanoma. Cancer Res. 56:254-258.
23. Basta, M., and C. H. Hammer. 1991. A rapid FPLC method for purification of the third component of human and guinea pig complement. J. Immunol. Methods 142:39-44.
24. Oikonomopoulou, K., K. K. Hansen, A. Baruch, M. D. Hollenberg, and E. P. Diamandis. 2008. Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids. Biol. Chem. 389:747-756.
25. Oikonomopoulou, K., K. K. Hansen, M. Saifeddine, I. Tea, M. Blaber, S. I. Blaber, I. Scarisbrick, P. Andrade-Gordon, G. S. Cottrell, N. W. Bunnett, et al. 2006. Proteinase-activated receptors, targets for kallikrein signaling. J. Biol. Chem. 281:32095-32112.
26. Reis, E. S., H. Chen, G. Sfyroera, P. N. Monk, J. Köhl, D. Ricklin, and J. D. Lambris. 2012. C5a receptor-dependent cell activation by physiological concentrations of desarginated C5a: insights from a novel label-free cellular assay. J. Immunol. 189:4797-4805.
27. Shamah, S. M., and B. T. Cunningham. 2011. Label-free cell-based assays using photonic crystal optical biosensors. Analyst 136:1090-1102.
28. Goettig, P., V. Magdolen, and H. Brandstetter. 2010. Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie 92:1546-1567.
29. Circolo, A., G. Garnier, W. Fukuda, X. Wang, T. Hidvegi, A. J. Szalai, D. E. Briles, J. E. Volanakis, R. A. Wetsel, and H. R. Colten. 1999. Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology 42:135-149.
30. Hopken, U. E., B. Lu, N. P. Gerard, and C. Gerard. 1996. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 383:86-89.
31. Kildsgaard, J., T. J. Hollmann, K. W. Matthews, K. Bian, F. Murad, and R. A. Wetsel. 2000. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxinshock. J. Immunol. 165:5406-5409.
32. Brattsand, M., K. Stefansson, C. Lundh, Y. Haasum, and T. Egelrud. 2005. A proteolytic cascade of kallikreins in the stratum corneum. J. Invest. Dermatol. 124:198-203.
33. Bokisch, V. A., M. P. Dierich, and H. J. Muller-Eberhard. 1975. Third component of complement (C3): structural properties in relation to functions. Proc. Natl. Acad. Sci. USA 72:1989-1993.
34. Paszcuk, A. F, N. L. Quintao, E. S. Fernandes, L. Juliano, K. Chapman, P. Andrade-Gordon, M. M. Campos, N. Vergnolle, and J. B. Calixto. 2008. Mechanisms underlying the nociceptive and inflammatory responses induced by trypsin in the mouse paw. Eur. J. Pharmacol. 581:204-215.
35. Oikonomopoulou, K., K. K. Hansen, M. Saifeddine, N. Vergnolle, I. Tea, M. Blaber, S. I. Blaber, I. Scarisbrick, E. P. Diamandis, and M. D. Hollenberg. 2006. Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol. Chem. 387:817-824.
36. Oikonomopoulou, K., K. K. Hansen, K. Chapman, N. Vergnolle, E. P. Diamandis, and M. D. Hollenberg. 2007. Kallikrein-mediated activation of PARs in inflammation and nociception. Inflamm. Res. 56:S499-S502.
37. Fukuoka, Y., and T. E. Hugli. 1990. Anaphylatoxin binding and degradation by rat peritoneal mast cells. Mechanisms of degranulation and control. J. Immunol. 145:1851-1858.
38. Mousli, M., T. E. Hugli, Y. Landry, and C. Bronner. 1992. A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J. Immunol. 148:2456-2461.
39. Gratio, V., C. Loriot, G. D. Virca, K. Oikonomopoulou, F. Walker, E. P. Diamandis, M. D. Hollenberg, and D. Darmoul. 2011. Kallikrein-related peptidase 14 acts on proteinase-activated receptor 2 to induce signaling pathway in colon cancer cells. Am. J. Pathol. 179:2625-2636.
40. Borgoño, C. A., I. P. Michael, J. L. Shaw, L. Y. Luo, M. C. Ghosh, A. Soosaipillai, L. Grass, D. Katsaros, and E. P. Diamandis. 2007. Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J. Biol. Chem. 282:2405-2422.
41. Vergnolle, N., M. D. Hollenberg, K. A. Sharkey, and J. L. Wallace. 1999. Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br. J. Pharmacol. 127:1083-1090.
42. Ames, R. S., D. Lee, J. J. Foley, A. J. Jurewicz, M. A. Tornetta, W. Bautsch, B. Settmacher, A. Klos, K. F. Erhard, R. D. Cousins, et al. 2001. Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J. Immunol. 166:6341-6348.
43. Clark, J. D., Y. Qiao, X. Li, X. Shi, M. S. Angst, and D. C. Yeomans. 2006. Blockade of the complement C5a receptor reduces incisional allodynia, edema, and cytokine expression. Anesthesiology 104:1274-1282.
44. Stefansson, K., M. Brattsand, D. Roosterman, C. Kempkes, G. Bocheva, M. Steinhoff, and T. Egelrud. 2008. Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases. J. Invest. Dermatol. 128:18-25.
45. Briot, A., M. Lacroix, A. Robin, M. Steinhoff, C. Deraison, and A. Hovnanian. 2010. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model. J. Invest. Dermatol. 130:2736-2742.
46. Ramachandran, R., F. Noorbakhsh, K. Defea, and M. D. Hollenberg. 2012. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat. Rev. Drug Discov. 11:69-86.
47. Ricklin, D., and J. D. Lambris. 2013. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 190:3831-3838.
48. S. Reis, E., D. A. Falcão, and L. Isaac. 2006. Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand. J. Immunol. 63:155-168.
49. Shaw, J. L., and E. P. Diamandis. 2007. Distribution of 15 human kallikreins in tissues and biological fluids. Clin. Chem. 53:1423-1432.
50. Krisinger, M. J., V. Goebeler, Z. Lu, S. C. Meixner, T. Myles, E. L. Pryzdial, and E. M. Conway. 2012. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 120:1717-1725.
51. Blaber, M., H. Yoon, M. A. Juliano, I. A. Scarisbrick, and S. I. Blaber. 2010. Functional intersection of the kallikrein-related peptidases (KLKs) and thrombostasis axis. Biol. Chem. 391:311-320.
52. Oikonomopoulou, K., D. Ricklin, P. A. Ward, and J. D. Lambris. 2012. Interactions between coagulation and complement-their role in inflammation. Semin. Immunopathol. 34:151-165.